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Abstract: AIMS Cardiac myosin-binding protein C (cMyC) seems to be even more sensitive in the
quantification of cardiomyocyte injury vs. high-sensitivity cardiac troponin, and may therefore have
diagnostic and prognostic utility. METHODS AND RESULTS In a prospective multicentre diagnostic
study, cMyC, high-sensitivity cardiac troponin T (hs-cTnT), and N-terminal pro-B-type natriuretic pep-
tide (NT-proBNP) plasma concentrations were measured in blinded fashion in patients presenting to the
emergency department with acute dyspnoea. Two independent cardiologists centrally adjudicated the
final diagnosis. Diagnostic accuracy for acute heart failure (AHF) was quantified by the area under the
receiver operating characteristic curve (AUC). All-cause mortality within 360 days was the prognostic
endpoint. Among 1083 patients eligible for diagnostic analysis, 51% had AHF. cMyC concentrations at
presentation were higher among AHF patients vs. patients with other final diagnoses [72 (interquartile
range, IQR 39-156) vs. 22 ng/L (IQR 12-42), P < 0.001)]. cMyC’s AUC was high [0.81, 95% confidence
interval (CI) 0.78-0.83], higher than hs-cTnT’s (0.79, 95% CI 0.76-0.82, P = 0.081) and lower than NT-
proBNP’s (0.91, 95% CI 0.89-0.93, P < 0.001). Among 794 AHF patients eligible for prognostic analysis,
28% died within 360 days; cMyC plasma concentrations above the median indicated increased risk of
death (hazard ratio 2.19, 95% CI 1.66-2.89; P < 0.001). cMyC’s prognostic accuracy was comparable
with NT-proBNP’s and hs-cTnT’s. cMyC did not independently predict all-cause mortality when used
in validated multivariable regression models. In novel multivariable regression models including medi-
cation, age, left ventricular ejection fraction, and discharge creatinine, cMyC remained an independent
predictor of death and had no interactions with medical therapies at discharge. CONCLUSION Cardiac
myosin-binding protein C may aid physicians in the rapid triage of patients with suspected AHF.
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Aims Cardiac myosin-binding protein C (cMyC) seems to be even more sensitive in the quantification of cardiomyocyte
injury vs. high-sensitivity cardiac troponin, and may therefore have diagnostic and prognostic utility.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
In a prospective multicentre diagnostic study, cMyC, high-sensitivity cardiac troponin T (hs-cTnT), and N-terminal
pro-B-type natriuretic peptide (NT-proBNP) plasma concentrations were measured in blinded fashion in patients
presenting to the emergency department with acute dyspnoea. Two independent cardiologists centrally adjudicated
the final diagnosis. Diagnostic accuracy for acute heart failure (AHF) was quantified by the area under the receiver
operating characteristic curve (AUC). All-cause mortality within 360 days was the prognostic endpoint. Among 1083
patients eligible for diagnostic analysis, 51% had AHF. cMyC concentrations at presentation were higher among
AHF patients vs. patients with other final diagnoses [72 (interquartile range, IQR 39–156) vs. 22 ng/L (IQR 12–42),
P< 0.001)]. cMyC’s AUC was high [0.81, 95% confidence interval (CI) 0.78–0.83], higher than hs-cTnT’s (0.79,
95% CI 0.76–0.82, P= 0.081) and lower than NT-proBNP’s (0.91, 95% CI 0.89–0.93, P< 0.001). Among 794 AHF
patients eligible for prognostic analysis, 28% died within 360 days; cMyC plasma concentrations above the median
indicated increased risk of death (hazard ratio 2.19, 95% CI 1.66–2.89; P< 0.001). cMyC’s prognostic accuracy was
comparable with NT-proBNP’s and hs-cTnT’s. cMyC did not independently predict all-cause mortality when used
in validated multivariable regression models. In novel multivariable regression models including medication, age, left
ventricular ejection fraction, and discharge creatinine, cMyC remained an independent predictor of death and had
no interactions with medical therapies at discharge.
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Introduction
Acute heart failure (AHF) is the most common diagnosis in the
emergency department (ED) leading to hospitalization.1,2 In con-
trast to the enormous improvements achieved in the management
of patients with chronic heart failure, morbidity and mortality
remain unacceptably high in patients with AHF. Specifically, the
combination of all-cause mortality or recurrent hospitalization at
6 months approaches 50%.1–3 The dismal outcome of patients with
AHF may be at least in part related to diagnostic and prognostic
uncertainty in the ED and the associated delay in the identification
of patients for early and effective treatments and an incomplete
understanding of the pathophysiological mechanisms involved
in the AHF syndromes, which may require tailored therapeutic
strategies.4
Cardiovascular biomarkers incorporated in clinica practice
address some of these challenges. First, as quantitative markers of
haemodynamic stress and heart failure, natriuretic peptides have
substantially improved the rapid detection of AHF among patients
presenting with acute dyspnoea.1,2,5–8 Second, high-sensitivity
cardiac troponin (hs-cTn) concentrations allow quantification
of cardiomyocyte injury and enhance risk stratification of AHF
patients.6,9,10
Cardiac myosin-binding protein C (cMyC) (Figure 1) is a
novel biomarker that is unique to cardiomyocytes and can
possibly quantify cardiomyocyte injury even more accurately
than hs-cTn.11–13 In addition, it has shown promising diagnostic
and prognostic utility in the management of acute coronary
syndromes.11 cMyC may also have a role in the pathogenesis of
AHF as various animal models for hypertrophic cardiomyopathy
have shown that homozygous cMyC knock-out mice develop
heart failure.14 Definite pathogenic mutations within cMyC are
the most common genetic cause of hypertrophic cardiomyopathy,
responsible for 40–50% of new diagnoses.15 These mutations, and
known post-translational modifications of the cMyC protein, occur
outside the N-terminal C0 region of the protein which is used for
detection by the diagnostic assay.13,15,16 The fast release kinetics
of cMyC quantifying cardiomyocyte injury and its abundance in
cardiomyocytes led to the hypothesis that cMyC concentrations
may have diagnostic, prognostic, and therapy guidance potential in
patients with AHF.11,12,17
We, therefore, aimed to test this hypothesis in a large multi-
centre cohort of patients presenting to the ED with suspected
AHF.
Methods
Study population and design
Basics in Acute Shortness of Breath EvaLuation (BASEL V) was a
prospective, multicentre diagnostic study aimed at contributing to
advancing the early detection and management of patients with AHF
(ClinicalTrials.gov, NCT01831115).18,19 Adult patients presenting with
acute dyspnoea to the ED of two university hospitals and three further
tertiary care centres in Switzerland were enrolled (Basel, Zurich,
Lucerne, St. Gallen, and Aarau). While enrolment was independent of



















































































.. were excluded. For this analysis, patients were also excluded if they
did not have cMyC plasma concentrations measured from study blood
samples at ED presentation, if the final diagnosis remained unclear
even after central adjudication, or if the patients were adjudicated
as having cardiac dyspnoea due to an acute coronary syndrome or
arrhythmia without any other evidence of AHF. For the prognostic
analyses, patients with an adjudicated final diagnosis of AHF enrolled
in an AHF therapy study were also eligible if study blood was available
for the measurement of cMyC.20
The study was carried out according to the principles of the Decla-
ration of Helsinki and was approved by the local ethics committees. All
patients provided written informed consent. The authors designed the
study, gathered, and analysed the data according to the STARD guide-
lines for studies of diagnostic accuracy and the TRIPOD statement for
studies reporting multivariable prediction models for individual prog-
nosis (online supplementary Table S1),21,22 vouched for the data and
analysis, wrote the paper, and decided to submit it for publication.
Adjudication of the final diagnosis
The final underlying cause of shortness of breath was centrally
adjudicated by two independent cardiologists who had access to
all patients’ medical records (clinical history, physical examination,
12-lead electrocardiogram, laboratory findings including natriuretic
peptide measurements,1,2 estimated glomerular filtration rate, chest
X-ray, echocardiography, lung function testing, computed tomography,
response to therapy, and 360-day follow-up, according to current
guidelines).1,2 cMyC measurements were not available for the adju-
dication of the final diagnosis. In situations of disagreement related
to the diagnosis, cases were reviewed and adjudicated in conjunction
with a third cardiologist.
Patient follow-up
Patients were contacted after 90 days and at 1 year by telephone calls
or in written form by trained researchers, unaware of the patients’
cMyC plasma concentrations during the index hospitalization. In case of
a possible relevant medical event such as heart failure rehospitalization
or all-cause death during the follow-up period, further information was
obtained from the hospital records, general physician records, or the
national death registry.
Biochemical measurements
At ED presentation, blood samples were collected in tubes con-
taining heparin for the determination of cMyC and high-sensitivity
cardiac troponin T (hs-cTnT) concentrations, and potassium ethylene-
diaminetetraacetic acid for analysis of N-terminal pro-B-type natri-
uretic peptide (NT-proBNP), respectively. After centrifugation, sam-
ples were frozen at −80∘C until assayed in a blinded fashion in a
dedicated core laboratory. cMyC was measured using an established
high-sensitivity assay on the Erenna platform performed by Millipore
Sigma.13 The assay has a limit of detection of 0.4 ng/L and a lower
limit of quantification of 1.2 ng/L with a ≤20% coefficient of varia-
tion at limits of quantification, and ≤10% coefficient of variation at the
99th centile. Assay precision is not affected by freeze/thaw cycles.23
The 99th percentile concentration determined previously in patients
without obstructive coronary artery disease on invasive angiography
is 87 ng/L.11,13 In this study, the 99th centiles calculated for hs-cTnI/T
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Depiction of cardiac troponin and cardiac myosin-binding protein C (cMyC) release during myocardial injury. Structure of cMyC and
cardiac troponins in (A) healthy cardiomyocytes and (B) during cardiomyocyte injury. The highlighted N-terminal domain C0C1 is the binding
site for the previously developed monoclonal antibodies used for detection of the cardiac-specific isoform of cMyC.11 cTnC, cardiac troponin
C; cTnI, cardiac troponin I; cTnT, cardiac troponin T.
matched the established thresholds. The hs-cTnT assay (Elecsys 2010
high-sensitivity troponin T, Roche Diagnostics, Rotkreuz, Switzerland)
has a 99th percentile concentration of 14 ng/L.24 NT-proBNP con-
centrations were measured using the Elecsys proBNP assay (Elec-
sys proBNP, Roche Diagnostics AG, Rotkreuz, Switzerland). The
intra-assay coefficients of variation ranged from 1.8% to 2.7% and from
2.4% to 3.2% for within-run and total imprecision, respectively.25 The
laboratory technicians whomeasured cMyC, hs-cTnT, and NT-proBNP
were blinded to the clinical data of the patients.
Outcome measures
The diagnostic accuracy for AHF quantified by the area under the
receiver operating characteristic curve (AUC) was the primary diag-
nostic outcome measure. Only patients with confirmed final diagnosis
of AHF were eligible for the prognostic analyses. The primary prog-
nostic outcome measure was the utility of cMyC to predict all-cause
mortality in AHF patients within 360 days. Secondary outcome mea-
sures were the prediction of AHF rehospitalizations; the combination
of all-cause mortality or AHF rehospitalizations; the identification
of AHF phenotypes according to cMyC plasma concentrations with
disproportional benefit or harm in terms of all-cause mortality during
the 360-day follow-up in pre-defined subgroups according to their

































. (ACE-I) or angiotensin receptor blockers (ARB), beta-blockers, aldos-
terone antagonists, calcium channel blockers, and digoxin at hospital
discharge; the diagnostic and prognostic performance in the subgroup
of patients with renal dysfunction.
Assessment of renal function
For this analysis, renal dysfunction was defined as estimated glomerular
filtration rate <60mL/min/1.73m2 at presentation to the ED and
was calculated by using the Chronic Kidney Disease Epidemiology
Collaboration formula.
Statistical methods
The Kolmogorov–Smirnov test and visual inspection of the shape of
the distribution of the variables were used to assess their normality.
Continuous variables are presented as medians with interquartile range
(IQR) as appropriate. Categorical variables are presented as numbers
and percentages. Comparisons between groups were made using the
Chi-square test, the Mann–Whitney U test, or the Kruskal–Wallis
test as appropriate. Comparison of the AUCs of cMyC, hs-cTnT,
and NT-proBNP was performed as recommended by DeLong et al.26
The diagnostic accuracy of the combination of cMyC and NT-proBNP
was assessed by logistic regression analysis. The optimal cMyC cut-off
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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concentration for the rapid rule out of AHF was derived from the
receiver operating characteristic (ROC) curve. The requirements for
this cut-off concentration were imposed by clinical considerations:
a minimum sensitivity was set as high as 95% because of the large
potential adverse outcome of missing a patient with AHF. The rel-
evant 95% confidence intervals (CIs) of the predictive values were
defined by using the Wilson score method without continuity cor-
rection. The utility of cMyC to predict all-cause mortality in AHF
patients was assessed by comparing the time-dependent ROC curves
of cMyC, hs-cTnT, and NT-proBNP.27 All-cause mortality and AHF
rehospitalization as well as the combination of both endpoints dur-
ing follow-up were plotted in Kaplan–Meier curves, and the log-rank
test was used to assess differences between groups. Spearman’s rho
was used to analyse correlations between cMyC and selected vari-
ables. cMyC and pre-defined variables from validated risk models to
predict all-cause mortality, or the combination of all-cause mortality
or hospitalizations due to AHF were entered in multivariable Cox pro-
portional hazard models.28 In contrast to the validated risk model for
the prediction of the combination of all-cause mortality or hospital-
izations due to AHF, high-density lipoprotein plasma concentrations
at baseline were not available. Interactions between cMyC plasma con-
centrations and treatment with diuretics, ACE-I or ARB, beta-blockers,
and aldosterone antagonists at hospital discharge were explored. The
interaction of P-values between biomarker plasma concentrations and
the pre-defined AHF subgroups according to their medication on dis-
charge was calculated in bivariable Cox proportional hazards models.
These bivariable models were then further adjusted for age, left ven-
tricular ejection fraction (LVEF) and creatinine plasma concentrations
at discharge. Hazard ratios are presented with 95% CI. Subgroup analy-
ses were performed in patients with renal dysfunction to compare the
diagnostic and prognostic accuracy of cMyC, hs-cTnT, and NT-proBNP.
This was an exploratory analysis within a prospective study, and sam-
ple size of the overall cohort was not specifically determined for this
analysis. No imputation was performed for missing values. Patients
without complete 1-year clinical follow-up were censored at the time
of the last known contact. Statistical analyses were performed using
SPSS/PC Software Package (version 25.0) and R Statistical Software
(version 3.5.1), including packages ‘pROC’, ‘timeROC’, ‘cmprsk’, ‘sur-
vival’, ‘ggplot’, ‘tableone’, ‘haven’, ‘tibble’, and ‘predictABLE’.
Results
Patient demographics and characteristics
A total of 1330 patients were enrolled between November
2007 and August 2013. Of these, 1083 were eligible for the
diagnostic analysis (online supplementary Figure S1). In the overall
cohort, the median age was 75 years, and 42% of all patients
were women (Table 1). Roughly one third (35%) of the patients
had a history of AHF, and 41% had known coronary artery
disease.
Acute heart failure and cardiac
myosin-binding protein C plasma
concentrations
Acute heart failure was the adjudicated final diagnosis in 548
patients (51%) included in the diagnostic analysis and in 794



















































































.. presentation were higher among patients with AHF vs. patients
with other final diagnosis [72 (IQR 39–156) vs. 22 (IQR 12–42)
ng/L, P< 0.001]. Among the different AHF phenotypes, acute coro-
nary syndrome with AHF, and pulmonary oedema were associ-
ated with even higher cMyC concentrations (online supplementary
Table S2). cMyC plasma concentrations showed a strong corre-
lation with hs-cTnT (0.792, P< 0.001) and NT-proBNP (0.691,
P< 0.001) concentrations, and a modest correlation with cardiac
structure and function as quantified by LVEF (−0.320, all P< 0.001;
online supplementary Table S3).
Among the non-AHF causes of acute dyspnoea, pulmonary
embolism [61 (IQR 28–144) ng/L, n = 56] had higher cMyC
concentrations vs. exacerbated obstructive pulmonary disease [20
(IQR 11–37) ng/L, n = 161] and pneumonia (24 (12–44) ng/L,
n = 114) (online supplementary Table S4).
Beyond the presence or absence of AHF, when comparing dif-
ferent cMyC quartiles, patients with higher plasma concentrations
were more likely to be older and to have prior history of coro-
nary artery disease. Patients in the top cMyC quartile also had a
lower LVEF, and higher NT-proBNP as well as higher creatinine
concentrations (online supplementary Table S5).
Diagnostic performance
A total of 1083 patients were eligible for diagnostic analysis (online
supplementary Figure S1 and Table S6). The diagnostic accuracy of
cMyC plasma concentrations to diagnose AHF as quantified by the
AUC was high (0.81, 95% CI 0.78–0.83), higher than hs-cTnT’s
(0.79, 95% CI 0.76–0.82, P = 0.081) and lower vs. NT-proBNP’s
(0.91, 95% CI 0.89–0.93, P< 0.001; Figure 2). The combination
of cMyC and NT-proBNP did not further increase the AUC of
NT-proBNP (0.91, 95%CI 0.89–0.93, P= 0.697). Subgroup analysis
in patients with renal dysfunction demonstrated a reduction of
diagnostic accuracy of all the biomarkers in the presence of renal
dysfunction; however, the difference between hs-cTnT and cMyC
increased (0.69 for hs-cTnT, 95% CI 0.63–0.74 vs. 0.75 for cMyC,
95% CI 0.70–0.80, respectively; P< 0.001; online supplementary
Figure S2).
The pre-defined minimum sensitivity of 95% was achieved at
the cMyC cut-off concentration of 16 ng/L. By using this cut-off
concentration to exclude the diagnosis of AHF, its sensitivity was
95% (95% CI 93–97%), the negative predictive value was 88% (95%
CI 84–92%), and it enabled rule out of 21% (95% CI 18–23%)
of the patients. In turn, when using the currently recommended
rule-out cut-off for NT-proBNP at 300 pg/mL, the achieved sen-
sitivity and negative predictive value were as high as 98% (95% CI
97–99%) and 97% (95% CI 94–98%), respectively. Furthermore,
it allowed to rule out 28% (95% CI 25–31%) of the patients
(Table 2).
Prognostic implications
Among 1330 patients in the overall cohort, 794 AHF patients were
eligible for prognostic analysis (online supplementary Figure S1).
Of these patients, 790 (99%) had a complete follow-up and a
total of 223 (28%) died within the 360-day follow-up period.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 illustrates the patients’ characteristics according to
their survival status for the 360-day period. Patients who died
within the 360-day follow-up were older, had a lower body
mass index, lower blood pressure, and more often had a his-








. plasma concentrations were substantially higher as compared to
survivors.
Patients with AHF and cMyC plasma concentrations above the
median were at increased risk of death (hazard ratio 2.19, 95% CI
1.66–2.89; P< 0.001; Figure 3), which is comparable to hs-cTnT
Table 1 Baseline characteristics of the patients presenting to the emergency department with acute dyspnoea
grouped by an adjudicated final diagnosis of acute heart failure
All patients (n = 1330) AHF (n = 794) No AHF (n = 536) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographics
Age (years) 75 (63–83) 79 (70–85) 66 (54–77) <0.001
Female sex 554 (42) 322 (40.6) 232 (43) 0.350
Weight (kg) 76 (65–88) 76 (65–88) 75 (63–87) 0.163
BMI (kg/m2) 26 (23–30) 27 (24–30) 26 (22–30) 0.001
Clinical parameters at ED
SBP (mmHg) 135 (120–153) 135 (120–153) 136 (121–152) 0.658
Heart rate (bpm) 89 (75–105) 87 (72–105) 93 (80–106) <0.001
Respiratory rate (breaths/min) 22 (18–28) 22 (18–28) 23 (18–28) 0.504
Pulse oximetry (%) 96 (93–98) 96 (93–98) 95 (92–98) 0.330
Temperature (∘C) 37.1 (36.6–37.6) 37.0 (36.5–37.4) 37.3 (36.8–37.8) <0.001
LVEF (%) 50 (33–60) 45 (30–55) 60 (55–62) <0.001
Medical history
Hypertension 951 (72) 669 (85) 282 (53) <0.001
Dyslipidaemia 642 (50) 462 (60) 180 (34) <0.001
CAD 539 (41) 433 (55) 106 (20) <0.001
Prior myocardial infarction 319 (24) 260 (34) 59 (11) <0.001
Prior AHF 455 (35) 395 (50) 60 (11) <0.001
Atrial fibrillation 432 (33) 378 (48) 54 (10) <0.001
CKD 446 (34) 367 (46) 79 (15) <0.001
PAD 155 (12) 123 (16) 32 (6.0) <0.001
Stroke 156 (12) 120 (15) 36 (6.7) <0.001
COPD 418 (32) 185 (23) 233 (44) <0.001
Medication at admission
ACE inhibitors 431 (33) 322 (42) 109 (21) <0.001
ARBs 293 (23) 206 (27) 87 (17) <0.001
Beta-blockers 634 (49) 490 (63) 144 (27) <0.001
Aldosterone antagonists 112 (8.6) 93 (12) 19 (3.6) <0.001
CCB 252 (19) 173 (22) 79 (15) 0.001
Digoxin 52 (4.0) 46 (6.0) 6 (1.1) <0.001
Diuretics 702 (54) 544 (70) 158 (30) <0.001
Laboratory parameters
Haemoglobin (g/L) 131 (116–144) 126 (111–139) 139 (126–149) <0.001
Haematocrit (%) 38 (35–42) 37 (34–41) 40 (37–43) <0.001
Sodium (mmol/L) 139 (136–141) 139 (137–142) 138 (136–141) <0.001
Chloride (mmol/L) 101 (98–104) 102 (98–105) 100 (96–103) <0.001
Potassium (mmol/L) 4.1 (3.8–4.4) 4.2 (3.8–4.5) 4.0 (3.7–4.3) <0.001
Creatinine (μmol/L) 92 (73–126) 106 (81–147) 79 (63–96) <0.001
Urea (mmol/L) 8.3 (5.7–12) 9.8 (6.9–14) 6.3 (4.5–8.7) <0.001
Albumin (g/L) 36 (32–38) 35 (32–38) 36 (33–40) 0.001
NT-proBNP (ng/L) 2473 (374–6628) 5250 (2592–9747) 231(80–835) <0.001
hs-cTnT (ng/L) 26 (12–50) 37 (21–67) 13 (6–26) <0.001
cMyC (ng/L) 46 (22–104) 72 (39–156) 22 (12–42) <0.001
Values are given as median (interquartile range), or n (%).
ACE, angiotensin-converting enzyme; AHF, acute heart failure; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; CCB, calcium
channel-blocker; CKD, chronic kidney disease; cMyC, cardiac myosin-binding protein C; COPD, chronic obstructive pulmonary disease; ED, emergency department; hs-cTnT,
high-sensitivity cardiac troponin T; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAD, peripheral arterial disease; SBP, systolic
blood pressure.
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1 - Specificity















cMyC, AUC 0.81 (0.78-0.83)
NT-proBNP, AUC 0.91 (0.89-0.93)
hs-cTnT, AUC 0.79 (0.76-0.82)
Figure 2 Receiver operating characteristic curve comparison of
cardiac myosin-binding protein C (cMyC) with high-sensitivity car-
diac troponin T (hs-cTnT) (P= 0.081) or N-terminal pro-B-type
natriuretic peptide (NT-proBNP) (P< 0.001) in patients in
the diagnostic cohort with biomarker measurements available
(n = 1060) for the diagnosis of acute heart failure in the emer-
gency department. AUC, area under the curve.
Table 2 Performance of the cardiac myosin-binding
protein C cut-off concentration of 16ng/L for the
rapid exclusion of acute heart failure among patients





. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sensitivity, % (95% CIb) 95 (93–97) 98 (97–99)
Specificity, % (95% CI) 37 (33–41) 55 (51–59)
NPV, % (95% CI) 88 (84–92) 97 (94–98)
PPV, % (95% CI) 61 (57–64) 69 (66–73)
Negative likelihood ratio 0.13 (0.09–0.19) 0.03 (0.02–0.06)
Positive likelihood ratio 1.51 (1.41–1.61) 2.19 (1.98–2.40)
Diagnostic odds ratio 11.70 (7.60–18.01) 72.18 (36.54–142.59)
Patients ruled out,
n (%, 95% CI)
223 (21, 18–23) 289 (28, 25–31)
CI, confidence interval; cMyC, cardiac myosin-binding protein C; NPV, negative predictive
value; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PPV, positive predictive value.
a ‘Rule-out’ cut-off at 300 pg/mL.
bThe method used to calculate the CI for a proportion is the Wilson score method without
continuity correction.
(hazard ratio 2.61, 95% CI 1.95–3.51; P< 0.001) and NT-proBNP
(hazard ratio 2.28, 95% CI 1.72–3.03; P< 0.001). Similarly, cMyC
above the median was associated with higher rates of all-cause mor-
tality and AHF rehospitalization within 360 days (hazard ratio 1.63,
95% CI 1.31–2.02; P< 0.001; online supplementary Figure S3).
Cardiac myosin-binding protein C and NT-proBNP plasma con-



















































































.. classifying patients according to below/above the median of each
biomarker (P< 0.001; online supplementary Figure S4). Patients
with both cMyC and NT-proBNP concentrations above the median
had the highest risk of death, whereas AHF patients with low
plasma concentrations of both biomarkers had the lowest risk of
death. Similar results were obtained for the combination of cMyC
and hs-cTnT (online supplementary Figure S5).
The prognostic accuracy of cMyC, hs-cTnT, and NT-proBNP for
predicting all-cause mortality, the combination of all-cause mor-
tality and AHF rehospitalization as well as AHF rehospitalizations
alone along the 360 days were, overall, comparable using their
time-dependent ROC curves (Figure 4 and online supplemen-
tary Figure S6). Notably, in the subgroup of patients with renal
dysfunction, cMyC showed better prognostic performance for
the short-term prognosis as compared to NT-proBNP (AUCs at
15 days 0.826 vs. 0.686, P = 0.007; online supplementary Figure S7).
The combination of NT-proBNP or hs-cTnT with cMyC did not sig-
nificantly increase their prognostic accuracy for predicting all-cause
mortality or its combination with AHF hospitalisations (online sup-
plementary Figures S8 to S11). Variables from validated risk models
to predict all-cause mortality or their combination with hospitaliza-
tions due to AHF were entered in multivariable regression models
(Tables 4 and 5). cMyC was not an independent predictor for these
outcomes after multivariable adjustment.
Interaction with treatment at hospital
discharge
In bivariable Cox proportional hazards models, a significant
interaction was found between cMyC plasma concentrations
at presentation and treatment with ACE-I at discharge (online
supplementary Table S7A). After multivariable adjustment including
age, LVEF, and creatinine plasma concentrations at discharge, the
interactions regarding cMyC plasma concentrations lost their
statistical significance (online supplementary Table S7B).
Discussion
This secondary analysis within a large prospective diagnostic study
aimed to evaluate the clinical utility of cMyC in the diagnosis, risk
stratification and therapy guidance of patients with AHF.1,2 We
report six major findings.
First, in line with our hypothesis, cMyC concentrations were
higher in patients with an adjudicated final diagnosis of AHF vs.
patients with other causes of acute dyspnoea. In the context
of the ability of cMyC to precisely quantify cardiac injury, this
finding is in full agreement with the previously reported high
incidence of elevated hs-cTn concentrations in AHF.2,9,10 Second,
the diagnostic accuracy of cMyC for AHF was high, being slightly
higher than hs-cTnT, but lower than the current laboratory gold
standard for NT-proBNP. Third, cMyC might help in better AHF
phenotyping, as the concentrations were higher in more severe
forms such as pulmonary oedema and AHF combined with acute
coronary syndrome. Fourth, all-cause mortality was higher in
patients with above median cMyC concentrations. Overall, the
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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prognostic accuracy was moderate-to-high and comparable to that
of NT-proBNP and hs-cTnT, with some incremental prognostic
value on top of NT-proBNP or hs-cTnT. However, in the fully
adjusted multivariable prediction model, cMyC was no longer an






.. proportional hazards models, a significant interaction between
cMyC plasma concentrations at presentation and treatment with
ACE-I at discharge was found, indicating that patients with higher
cMyC concentrations might derive particular long-term benefits
from these drugs. As the interaction was no longer significant
Table 3 Prognostic analyses of patient characteristics according to survival status of acute heart failure patients at
360days
Overall (n = 794) Dead at 360days (n = 223) Alive at 360days (n = 571) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographics
Age (years) 79 (70–85) 83 (76–87) 77 (67–84) <0.001
Female sex 322 (41) 103 (46) 219 (38) 0.052
Weight (kg) 76 (65–88) 69 (60–80) 79 (69–91) <0.001
BMI (kg/m2) 27 (24–30) 25(22–28) 27 (24–31) <0.001
Clinical parameters at ED
SBP (mmHg) 135 (120–153) 126 (111–146) 138 (123–155) <0.001
Heart rate (bpm) 87 (72–105) 85 (74–104) 87 (71–105) 0.907
Respiratory rate (breaths/min) 22 (18–28) 22 (20–28) 22 (18–28) 0.714
Pulse oximetry (%) 96 (93–98) 96 (92–98) 96 (93–98) 0.325
Temperature (∘C) 37.0 (36.5–37.4) 36.9 (36.5–37.5) 37.0 (36.5–37.4) 0.582
LVEF (%) 45 (30–55) 40 (27–55) 45 (30–55) 0.170
Medical history
Hypertension 669 (85) 188 (85) 481 (85) 0.939
Dyslipidaemia 462 (60) 130 (61) 332 (60) 0.801
CAD 433 (55) 131 (59) 302 (53) 0.138
Prior myocardial infarction 260 (34) 85 (39) 175 (32) 0.050
Prior AHF 395 (50) 128 (58) 267 (47) 0.004
Atrial fibrillation 378 (48) 103 (47) 275 (47) 0.656
CKD 367 (46) 127 (58) 240 (42) <0.001
PAD 123 (16) 41 (19) 82 (15) 0.144
Stroke 120 (15) 39 (18) 81 (14) 0.242
COPD 185 (23) 55 (25) 130 (23) 0.514
Medication at admission
ACE inhibitors 322 (42) 94 (44) 228 (41) 0.517
ARBs 206 (27) 49 (23) 157 (28) 0.117
Beta-blockers 490 (63) 132 (61) 358 (64) 0.388
Aldosterone antagonists 93 (12) 36 (17) 57 (10) 0.014
CCB 173 (22) 45 (21) 128 (23) 0.505
Digoxin 46 (6.0) 8 (3.8) 38 (6.8) 0.112
Diuretics 544 (70) 173 (79) 371 (67) <0.001
Laboratory parameters
Haemoglobin (g/L) 126 (111–139) 118.5 (109–131) 129 (114–142) <0.001
Haematocrit (%) 37 (34–41) 36 (33–39) 38 (34–42) <0.001
Sodium (mmol/L) 139 (137–142) 139 (137–141) 140 (137–142) 0.002
Chloride (mmol/L) 102 (98–105) 100 (97–104) 102 (99–105) 0.001
Potassium (mmol/L) 4.2 (3.8–4.5) 4.3 (3.9–4.7) 4.1 (3.8–4.5) 0.011
Creatinine (μmol/L) 106(81–147) 123(87–172) 100 (80–132) <0.001
Urea (mmol/L) 9.8 (6.9–13.9) 12.0(8.7–17.2) 9.1 (6.5–12.7) <0.001
Albumin (g/L) 35 (32–38) 34 (32–37) 36 (33–38) <0.001
NT-proBNP (ng/L) 5250 (2592–9746) 8096 (4089–18 329) 4491 (2220–8277) <0.001
hs-cTnT (ng/L) 37 (21–67) 53(33–102) 32 (19–58) <0.001
cMyC (ng/L) 72 (39–156) 119(52–263) 63 (34–127) <0.001
Values are given as median (interquartile range), or n (%).
ACE, angiotensin-converting enzyme; AHF, acute heart failure; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; cMyC, cardiac
myosin-binding protein C; CCB, calcium channel blocker; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ED, emergency department; hs-cTnT,
high-sensitivity cardiac troponin T; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAD, peripheral arterial disease; SBP, systolic
blood pressure.
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Hazard Ratio, 2.19 (95% CI, 1.66-2.89); p<0.001 
Figure 3 Cumulative mortality in acute heart failure patients
according to cardiac myosin-binding protein C (cMyC) plasma
concentrations above or below the median (72 ng/L, n = 794)


















Figure 4 Time-dependent receiver operating characteristic
(ROC) curves for all-cause mortality at 360 days for cardiac
myosin-binding protein C (cMyC), high-sensitivity cardiac tro-
ponin T (hs-cTnT), and N-terminal pro-B-type natriuretic peptide
(NT-proBNP) in acute heart failure patients (n = 748). There
were no significant differences between the areas under the curve
(AUC) of cMyC and hs-cTnT at 90, 180 and 360 days (P = 0.572,
0.075, and 0.079, respectively) or cMyC and NT-proBNP at 90,
180 and 360 days (P = 0.340, 0.234, and 0.090 respectively).
after multivariate adjustment including LVEF, the incremental value
of cMyC in the identification of AHF patients deriving long-term
benefits from ACE-I remains uncertain. Future studies assessing
dynamic changes in cMyC seem warranted, since the change
in concentrations may be more relevant for therapy guidance.29
The dynamic nature of cMyC, with its fast release kinetics and
abundance in cardiomyocytes, may provide a particular advantage
in this setting.11,12
To our knowledge, this is the first large prospective clinical
trial to explore the diagnostic and prognostic utility of cMyC
for AHF in adults and has demonstrated incremental value to its




















































































Table 4 Multivariable Cox proportional hazards
models for mortality at 360days in acute heart failure




. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 1.038 1.022–1.054 <0.001
Beta-blockers at baseline 0.849 0.629–1.145 0.283
lg BUN (mmol/L) 2.626 1.256–5.492 0.010
Haemoglobin (g/L) 0.998 0.991–1.005 0.542
lg NT-proBNP (ng/L) 2.737 1.812–4.135 <0.001
lg cMyC (ng/L) 1.290 0.983–1.693 0.067
AHF, acute heart failure; BUN, blood urea nitrogen; CI, confidence interval;
cMyC, cardiac myosin-binding protein C; NT-proBNP, N-terminal pro-B-type
natriuretic peptide.
Table 5 Multivariable Cox proportional hazards
models for mortality or acute heart failure (AHF)




. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 1.012 1.001–1.024 0.038
Prior AHF 1.259 0.994–1.594 0.057
Oedema 1.048 0.821–1.338 0.705
Beta-blockers at baseline 0.922 0.722–1.178 0.516
SBP (mmHg) 0.992 0.987–0.997 0.001
Haemoglobin (g/L) 0.999 0.994–1.004 0.619
Sodium (mmol/L) 0.988 0.963–1.013 0.339
lg NT-proBNP (ng/L) 1.956 1.446–2.645 <0.001
lg cMyC (ng/L) 1.231 0.986–1.538 0.067
AHF, acute heart failure; CI, confidence interval; cMyC, cardiac myosin-binding
protein C; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SBP, systolic
blood pressure.
previous work on the clinical use of cMyC for the diagnosis of
AHF in children. In a prospective case-control study that involved
50 children with AHF and 25 healthy children matched for age and
sex as a control group, the high diagnostic and prognostic value of
cMyC was demonstrated. With the use of a cut-off concentration
of 45 ng/mL, the sensitivity reached 100% and its specificity for
diagnosing AHF was 96%, while at the cut-off concentration of
152 ng/mL, its sensitivity and specificity for predicting adverse
outcomes were as high as 90% and 93%, respectively. The AUCwas
0.999 (95% CI 0.997–1.002) for the diagnosis and 0.915 (95% CI
0.796–1.034) for the prognosis of AHF.30 However, comparisons
between the results of the two studies should be assessed with
caution, mainly since the aetiology of AHF in children with a mean
age< 2 years in this study substantially differed when compared to
the elderly adult AHF population as in our study. BASEL V has
important methodological strengths including its large sample size,
highly representative elderly patient population for acute dyspnoea
and AHF,18,19 and adjudicated final diagnosis by two independent
cardiologists/internists according to current guidelines.1,2
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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This study also has several limitations. First, its findings are spe-
cific to patients presenting with acute dyspnoea to the ED, and
may not apply to the use of cMyC for screening in asymptomatic
patients or in patients presenting with very mild symptoms to a
general practitioner.1,2 Further studies are necessary to address
uncertainties regarding cut-off concentrations in these settings.
Second, despite using a very strong methodology for the central
adjudication of the final diagnosis, a very small number of patients
may still have been misclassified. This would have led to an under-
estimation of the diagnostic accuracy of cMyC. Third, in order to
maximize the accuracy in the adjudication of the final diagnosis
leading to ED presentation with dyspnoea in BASEL V, central adju-
dication included BNP or NT-proBNP measurements, putting the
blinded cMyC measurement at a disadvantage for direct compari-
son of diagnostic accuracy. Accordingly, the real difference in diag-
nostic accuracy between cMyC and NT-proBNP may be smaller
than found in this study. Fourth, further studies are needed to
prospectively validate the cut-offs for the optimal clinical use of
cMyC for the diagnosis and prognosis of AHF in the ED, taking into
account clinical characteristics that could potentially confound the
performance of cMyC. Accordingly, as a biomarker in the evalua-
tion of patients presenting with possible AHF, cMyC should always
be used in conjunction with all other clinical information. Fifth,
this study required written informed consent. Therefore, as for all
studies requiring written informed consent, selection bias towards
the enrolment of patients eligible to provide consent was unavoid-
able. Sixth, while enrolment was independent from renal function,
and a substantial number of patients with renal dysfunction were
included in this analysis, this study did not include patients with
terminal kidney failure on chronic haemodialysis. Accordingly, we
cannot comment on the performance of cMyC in this vulnerable
patient population.
In conclusion, this large multicentre diagnostic study using cen-
tral adjudication demonstrated that cMyC plasma concentrations
may aid physicians in the rapid triage of patients presenting to the
ED with suspected AHF.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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